Special Authority data by immunology indication
Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.
18 June 2020
[Name and contact details redacted]
Dear [Name redacted]
REQUEST FOR INFORMATION
Thank you for your emails of 18 May 2020 and 20 May 2020, in which you have requested the following data:
- Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.
This data you requested is attached. This information has been released pursuant to the Official Information Act 1982 (OIA).
Note that PHARMAC has changed a small amount of information to protect the privacy of natural persons (section 9(2)(a) of the OIA). This is when the data refers to numbers of less than 10 individuals. In these instances, the value has been changed to <10.
As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We are making our information more freely available, so we will now publish selected Official Information Act responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services
Special Authority SA1620 Etanercept
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Extraordinary Special Authority |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > ankylosing spondylitis |
<10 |
<10 |
<10 |
<10 |
11 |
<10 |
<10 |
Approved |
Initial |
Initial application > juvenile idiopathic arthritis |
<10 |
0 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > psoriatic arthritis |
14 |
10 |
10 |
14 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > rheumatoid arthritis |
25 |
18 |
18 |
13 |
14 |
15 |
12 |
Approved |
Initial |
Initial application > severe chronic plaque psoriasis |
<10 |
<10 |
<10 |
0 |
<10 |
0 |
<10 |
Approved |
Initial |
Initial application > pyoderma gangrenosum |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > adult-onset Still's disease |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > ankylosing spondylitis |
49 |
41 |
59 |
36 |
53 |
52 |
40 |
Approved |
Renewal |
Renewal > juvenile idiopathic arthritis |
11 |
14 |
15 |
10 |
17 |
18 |
12 |
Approved |
Renewal |
Renewal > psoriatic arthritis |
41 |
45 |
62 |
37 |
44 |
55 |
30 |
Approved |
Renewal |
Renewal > rheumatoid arthritis |
108 |
115 |
123 |
76 |
117 |
160 |
88 |
Approved |
Renewal |
Renewal > severe chronic plaque psoriasis |
17 |
23 |
12 |
16 |
21 |
18 |
17 |
Approved |
Renewal |
Renewal > pyoderma gangrenosum |
<10 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > adult-onset Still's disease |
<10 |
<10 |
<10 |
0 |
<10 |
0 |
<10 |
TOTAL |
278 |
280 |
311 |
208 |
283 |
333 |
218 |
Special Authority SA1742 Adalimumab
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Initial application > ankylosing spondylitis |
11 |
17 |
14 |
11 |
22 |
10 |
<10 |
Approved |
Initial |
Initial application > juvenile idiopathic arthritis |
<10 |
<10 |
<10 |
0 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > psoriatic arthritis |
<10 |
17 |
<10 |
<10 |
14 |
13 |
10 |
Approved |
Initial |
Initial application > rheumatoid arthritis |
20 |
29 |
21 |
33 |
27 |
17 |
<10 |
Approved |
Initial |
Initial application > severe chronic plaque psoriasis |
17 |
20 |
11 |
14 |
12 |
<10 |
<10 |
Approved |
Initial |
Initial application > fistulising Crohns disease |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > pyoderma gangrenosum |
0 |
<10 |
0 |
0 |
0 |
<10 |
0 |
Approved |
Initial |
Initial application > adult-onset Still's disease |
<10 |
0 |
0 |
0 |
0 |
0 |
<10 |
Approved |
Initial |
Initial application > Crohn's disease - adults |
34 |
15 |
34 |
17 |
14 |
32 |
16 |
Approved |
Initial |
Initial application > Crohn's disease - children |
<10 |
0 |
0 |
<10 |
0 |
0 |
<10 |
Approved |
Initial |
Initial application > uveitis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > Hidradenitis Suppurativa |
11 |
<10 |
<10 |
<10 |
<10 |
<10 |
0 |
Approved |
Renewal |
Renewal > ankylosing spondylitis |
127 |
117 |
134 |
92 |
112 |
165 |
92 |
Approved |
Renewal |
Renewal > juvenile idiopathic arthritis |
11 |
11 |
12 |
11 |
14 |
13 |
12 |
Approved |
Renewal |
Renewal > psoriatic arthritis |
80 |
94 |
100 |
91 |
77 |
124 |
79 |
Approved |
Renewal |
Renewal > rheumatoid arthritis |
185 |
183 |
196 |
158 |
132 |
221 |
138 |
Approved |
Renewal |
Renewal > severe chronic plaque psoriasis |
68 |
93 |
93 |
58 |
63 |
89 |
83 |
Approved |
Renewal |
Renewal > fistulising Crohns disease |
13 |
18 |
<10 |
<10 |
12 |
16 |
<10 |
Approved |
Renewal |
Renewal > pyoderma gangrenosum |
0 |
<10 |
<10 |
<10 |
0 |
<10 |
<10 |
Approved |
Renewal |
Renewal > adult-onset Still's disease |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Renewal |
Renewal > Crohn's disease - adults |
171 |
229 |
194 |
178 |
163 |
294 |
126 |
Approved |
Renewal |
Renewal > Crohn's disease - children |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Renewal |
Renewal > uveitis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > Hidradenitis Suppurativa |
<10 |
0 |
<10 |
<10 |
<10 |
<10 |
<10 |
TOTAL |
779 |
878 |
850 |
706 |
688 |
1,035 |
594 |
Special Authority SA1754 Secukinumab
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Initial application > severe chronic plaque psoriasis first-line biologic |
0 |
0 |
0 |
0 |
20 |
21 |
<10 |
Approved |
Initial |
Initial application > severe chronic plaque psoriasis second-line biologic |
0 |
0 |
0 |
0 |
14 |
<10 |
0 |
Approved |
Renewal |
Renewal > severe chronic plaque psoriasis first and second-line biologic |
0 |
0 |
0 |
0 |
55 |
56 |
53 |
TOTAL |
- |
- |
- |
- |
89 |
83 |
57 |
Special Authority SA1778 Infliximab
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Initial application > ankylosing spondylitis |
<10 |
<10 |
0 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > psoriatic arthritis |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > rheumatoid arthritis |
0 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > chronic ocular inflammation |
<10 |
0 |
<10 |
<10 |
0 |
<10 |
0 |
Approved |
Initial |
Initial application > previous use |
0 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > severe ocular inflammation |
0 |
0 |
0 |
0 |
0 |
0 |
<10 |
Approved |
Initial |
Initial application > Crohn's disease (adults) |
14 |
13 |
11 |
10 |
16 |
10 |
14 |
Approved |
Initial |
Initial application > Crohn's disease (children) |
0 |
<10 |
<10 |
0 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > Pulmonary sarcoidosis |
<10 |
0 |
0 |
<10 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > acute severe fulminant ulcerative colitis |
<10 |
<10 |
10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > fistulising Crohn's disease |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Initial |
Initial application > plaque psoriasis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > severe ulcerative colitis |
<10 |
<10 |
12 |
19 |
13 |
13 |
<10 |
Approved |
Initial |
Initial application > Graft vs host disease |
<10 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > neurosarcoidosis |
<10 |
0 |
<10 |
<10 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > severe Behcet's disease |
<10 |
<10 |
0 |
0 |
<10 |
0 |
0 |
Approved |
Renewal |
Renewal > ankylosing spondylitis |
19 |
<10 |
<10 |
11 |
13 |
34 |
18 |
Approved |
Renewal |
Renewal > psoriatic arthritis |
13 |
<10 |
<10 |
<10 |
<10 |
21 |
11 |
Approved |
Renewal |
Renewal > rheumatoid arthritis |
<10 |
<10 |
<10 |
<10 |
<10 |
16 |
11 |
Approved |
Renewal |
Renewal > chronic ocular inflammation |
<10 |
<10 |
<10 |
0 |
<10 |
<10 |
<10 |
Approved |
Renewal |
Renewal > previous use |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > severe ocular inflammation |
<10 |
<10 |
0 |
0 |
0 |
<10 |
0 |
Approved |
Renewal |
Renewal > Crohn's disease (adults) |
190 |
93 |
35 |
34 |
45 |
155 |
74 |
Approved |
Renewal |
Renewal > Crohn's disease (children) |
19 |
<10 |
<10 |
<10 |
<10 |
12 |
14 |
Approved |
Renewal |
Renewal > Pulmonary sarcoidosis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > severe fulminant ulcerative colitis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > fistulising Crohn's disease |
38 |
15 |
<10 |
<10 |
<10 |
20 |
10 |
Approved |
Renewal |
Renewal > plaque psoriasis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > severe ulcerative colitis |
150 |
55 |
20 |
27 |
45 |
145 |
61 |
Approved |
Renewal |
Renewal > Graft vs host disease |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > neurosarcoidosis |
<10 |
0 |
0 |
<10 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > severe Behcet's disease |
<10 |
0 |
0 |
0 |
0 |
<10 |
<10 |
TOTAL |
494 |
241 |
127 |
147 |
177 |
448 |
240 |
Special Authority SA1858 Tocilizumab
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Initial application > rheumatoid arthritis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Initial |
Initial application > all other applications |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
<10 |
Approved |
Renewal |
Renewal > rheumatoid arthritis |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Approved |
Renewal |
Renewal > all other applications |
52 |
17 |
<10 |
<10 |
34 |
83 |
37 |
Special Authority SA1818 Rituximab
Status |
Status |
Indication |
2019-10-01 |
2019-11-01 |
2019-12-01 |
2020-01-01 |
2020-02-01 |
2020-03-01 |
2020-04-01 |
Approved |
Initial |
Initial application > rheumatoid arthritis |
20 |
22 |
21 |
13 |
13 |
<10 |
<10 |
Approved |
Renewal |
Renewal > rheumatoid arthritis |
37 |
42 |
33 |
51 |
57 |
30 |
36 |